Saha Subha

Subha was born and raised in India where he completed his Masters in Biochemistry from the University of Calcutta, India. Thereafter, he joined the Ph.D. program at Institute of Life Sciences, to pursue a career in research. His past research work focused on the role of chromatin remodelling complexes in guiding differentiation  programs and lineage choices in hematopoiesis, and how these epigenetic switches can contribute to leukemic transformation. Presently, he is a postdoctoral fellow in Dr. Peter Miller's lab at Massachusetts General Hospital and Harvard Medical School.  Menin inhibitors (MIs), have recently emerged as an exciting new modality for treating AML. However, MIs are not curative and associated with toxicities like differentiation syndrome. His overachieving goal here is to dissect mechanisms of MIs and come up with combination strategies/targets that can improve the efficacy of MIs in order to achieve profound and long lasting responses in AML patients.